Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides caloric support and corrects hypoglycemia; sodium chloride replaces sodium and chloride ions to maintain electrolyte balance; potassium chloride replaces potassium for maintenance of normal cellular function.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Fluid and electrolyte replacement,Total parenteral nutrition,Treatment of hypokalemia when combined with appropriate monitoring,Maintenance of hydration in patients unable to take oral fluids
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion, typical adult dose: 1000-2000 m L per 24 hours, rate adjusted based on fluid and electrolyte status. Potassium chloride content provides 15 m Eq per liter; infusion rate should not exceed 10-20 m Eq/hr potassium.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Glucose: rapid, <15 min (physiologic turnover); Potassium: 6-8 h (intracellular redistribution phase); Sodium: prolonged, 24-48 h (dependent on renal function).
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Dextrose is metabolized to carbon dioxide and water via glycolysis and the citric acid cycle; sodium and potassium are excreted primarily by the kidneys; chloride is excreted as the anion.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Glucose is metabolized to carbon dioxide and water; potassium is primarily eliminated renally (90-95%) with minor fecal loss; sodium and chloride are excreted renally according to homeostasis.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Potassium: negligible (<5%); glucose: negligible; sodium and chloride: not bound.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Potassium: ~0.4-0.6 L/kg (total body water); glucose: ~0.2 L/kg (extracellular fluid); sodium: ~0.2-0.3 L/kg (extracellular space).
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
IV: 100% for all components.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
GFR > 50: No adjustment. GFR 30-50: Monitor serum potassium; rate reduction may be needed. GFR < 30: Use with caution; consider potassium restriction; avoid if oliguric.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
Child-Pugh A: No adjustment. Child-Pugh B/C: Use cautiously; monitor electrolytes due to potential fluid retention and electrolyte imbalances.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Weight-based: 0.45% sodium chloride with KCl 15 m Eq/L; typical maintenance: 100-150 m L/kg/24h for first 10 kg, then 50 m L/kg/24h for next 10 kg, then 20 m L/kg/24h for remaining weight; adjust potassium rate to 0.5-1 m Eq/kg/hr max.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Use lower initial infusion rates (e.g., 50-100 m L/hr) and frequent monitoring of serum electrolytes and renal function; potassium clearance may be reduced.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Not for use in patients with hyperkalemia, severe renal impairment, or conditions predisposing to hyperkalemia. Use in neonates may be associated with aluminum toxicity. Contains aluminum that may be toxic with prolonged administration in patients with impaired kidney function.
None
Use with caution in patients with heart failure, renal impairment, or conditions associated with fluid overload,Monitor serum electrolytes, fluid balance, and renal function,Risk of hyperkalemia, particularly in patients with impaired renal function or those receiving potassium-sparing diuretics,Avoid rapid infusion to prevent hyperglycemia and osmotic diuresis,Not for use in treating lactic acidosis or severe hyperglycemia
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hyperkalemia,Severe renal impairment (anuria or oliguria),Cellulitis or thrombophlebitis at infusion site,Addison's disease, severe burns, or other conditions that predispose to hyperkalemia,Hypersensitivity to any component
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
Avoid high-potassium foods (e.g., bananas, oranges, spinach) to prevent hyperkalemia. Monitor carbohydrate intake if diabetic; adjust insulin as needed.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Dextrose, sodium chloride, and potassium chloride are physiological components with no known teratogenic risk. Dextrose is a source of calories and is not associated with malformations. Sodium and potassium are essential ions; imbalances may occur but are not teratogenic. Potassium chloride at standard doses is not teratogenic. However, infusion of large volumes or high concentrations may cause maternal electrolyte disturbances that could indirectly affect the fetus. Use in pregnancy requires attention to maternal fluid and electrolyte status but presents no direct teratogenicity.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Dextrose, sodium chloride, and potassium chloride are normal constituents of breast milk. Intravenous administration of these components in clinically relevant doses does not significantly alter breast milk composition. The M/P (milk-to-plasma) ratio is not applicable as they are endogenous substances. Use during breastfeeding is considered safe; no lactation suppression or adjustment is needed.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy is associated with increased plasma volume (up to 50%), increased glomerular filtration rate, and altered electrolyte handling. While the drug composition is fixed, the volume of infusion may need adjustment to avoid fluid overload or dehydration. Glucose requirements increase; however, dextrose content is low (5%). No specific dose adjustment is recommended, but infusion rate should be titrated based on maternal electrolyte levels, fluid balance, and clinical response, particularly in preeclampsia or gestational diabetes where risks of hyperglycemia or fluid shifts are increased.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Administer via central line if concentration exceeds peripheral tolerance. Monitor potassium levels closely; risk of hyperkalemia in renal impairment. Do not use in patients with hyperkalemia or fluid overload. Use with caution in heart failure, renal failure, or conditions predisposing to hyperkalemia. Check serum osmolality and glucose in diabetic patients.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This solution contains dextrose (sugar) and potassium; inform your doctor if you have diabetes or kidney problems.,Report any signs of high potassium levels such as muscle weakness, irregular heartbeat, or tingling sensations.,You may experience increased urination or temporary weight gain due to fluid; report any shortness of breath or swelling.,Do not stop the infusion without consulting your healthcare provider.,Keep all appointments for blood tests to monitor your electrolytes and glucose.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides caloric support and corrects hypoglycemia; sodium chloride replaces sodium and chloride ions to maintain electrolyte balance; potassium chloride replaces potassium for maintenance of normal cellular function.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER is: Intravenous infusion, typical adult dose: 1000-2000 m L per 24 hours, rate adjusted based on fluid and electrolyte status. Potassium chloride content provides 15 m Eq per liter; infusion rate should not exceed 10-20 m Eq/hr potassium.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER is classified as Category A/B. Dextrose, sodium chloride, and potassium chloride are physiological components with no known teratogenic risk. Dextrose is a source of calories and is not associated with malformat. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.